CO5090908A1 - Procedimiento para administrar peptidos insulinotropicos - Google Patents

Procedimiento para administrar peptidos insulinotropicos

Info

Publication number
CO5090908A1
CO5090908A1 CO99053457A CO99053457A CO5090908A1 CO 5090908 A1 CO5090908 A1 CO 5090908A1 CO 99053457 A CO99053457 A CO 99053457A CO 99053457 A CO99053457 A CO 99053457A CO 5090908 A1 CO5090908 A1 CO 5090908A1
Authority
CO
Colombia
Prior art keywords
method
administering
glp
insulinotropic peptides
insulinotropic
Prior art date
Application number
CO99053457A
Other languages
English (en)
Inventor
Lee Benjamin Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US9827398P priority Critical
Priority to US10001298P priority
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5090908A1 publication Critical patent/CO5090908A1/es
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5090908(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Abstract

Un procedimiento para administrar una molécula del péptido 1 similar al glucagón (GLP-1 ), procedimiento que comprende administrar por vía pulmonar una cantidad eficaz de una molécula de GLP-1, seleccionada del grupo formado por GLP-1, análogos del GLP-1 o derivados del GLP-1, a un paciente que lo necesite.
CO99053457A 1998-08-28 1999-08-24 Procedimiento para administrar peptidos insulinotropicos CO5090908A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US9827398P true 1998-08-28 1998-08-28
US10001298P true 1998-09-11 1998-09-11

Publications (1)

Publication Number Publication Date
CO5090908A1 true CO5090908A1 (es) 2001-10-30

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99053457A CO5090908A1 (es) 1998-08-28 1999-08-24 Procedimiento para administrar peptidos insulinotropicos

Country Status (20)

Country Link
EP (1) EP0997151B1 (es)
JP (1) JP2002523466A (es)
CN (1) CN1314818A (es)
AR (1) AR022368A1 (es)
AT (1) AT347902T (es)
AU (1) AU764371B2 (es)
BR (1) BR9913284A (es)
CA (1) CA2341454A1 (es)
CO (1) CO5090908A1 (es)
CZ (1) CZ2001690A3 (es)
DE (1) DE69934380D1 (es)
EA (1) EA200100289A1 (es)
HR (1) HRP20010141A2 (es)
HU (1) HU0103369A3 (es)
IL (1) IL141241D0 (es)
NO (1) NO20010982L (es)
PE (1) PE20001031A1 (es)
PL (1) PL346317A1 (es)
TR (1) TR200100600T2 (es)
WO (1) WO2000012116A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP2003519664A (ja) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Glp−1誘導体の経上皮送達
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU6478901A (en) * 2000-06-08 2001-12-17 Lilly Co Eli Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
WO2002098348A2 (en) * 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
PL377687A1 (xx) * 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. アルブミン融合タンパク質
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
AU2003257156B2 (en) * 2002-08-01 2007-08-30 Mannkind Corporation Cell transport compositions and uses thereof
CA2549582A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
US7709639B2 (en) 2004-08-20 2010-05-04 Mannkind Corporation Catalysis of diketopiperazine synthesis
HUE026134T2 (en) 2004-08-23 2016-05-30 Mannkind Corp Microparticles comprising diketopiperazine salts for drug delivery
JP5465878B2 (ja) 2005-09-14 2014-04-09 マンカインド コーポレイション 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法
PT1965823T (pt) * 2005-11-04 2016-08-18 Glaxosmithkline Llc Métodos para administração de agentes hipoglicémicos
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR101736535B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Glp-1에 의한 유해 효과의 예방 방법
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2379100B1 (en) 2009-01-08 2014-11-12 MannKind Corporation Treating hyperglycemia with glp-1
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
NZ502358A (en) * 1997-07-18 2002-11-26 Infimed Therapeutics Inc Hydrogel composition comprising a biologically active substance combined with a macromer

Also Published As

Publication number Publication date
HRP20010141A2 (en) 2002-02-28
DE69934380D1 (de) 2007-01-25
EP0997151B1 (en) 2006-12-13
PE20001031A1 (es) 2000-10-12
TR200100600T2 (tr) 2001-07-23
AU764371B2 (en) 2003-08-14
AU5584199A (en) 2000-03-21
CN1314818A (zh) 2001-09-26
EA200100289A1 (ru) 2001-10-22
HU0103369A3 (en) 2002-03-28
AT347902T (de) 2007-01-15
WO2000012116A1 (en) 2000-03-09
JP2002523466A (ja) 2002-07-30
IL141241D0 (en) 2002-03-10
HU0103369A2 (hu) 2002-02-28
BR9913284A (pt) 2001-05-15
EP0997151A2 (en) 2000-05-03
EP0997151A3 (en) 2000-09-20
CZ2001690A3 (cs) 2002-04-17
CA2341454A1 (en) 2000-03-09
NO20010982L (no) 2001-04-27
NO20010982D0 (no) 2001-02-27
AR022368A1 (es) 2002-09-04
PL346317A1 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
KR937002022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
RU98118908A (ru) Баллон для доставки фармацевтического состава, дозирующий ингалятор
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
BR0015188A (pt) Composições farmacêuticas
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
NO326404B1 (no) Mikroemulsjoner, fremgangsmate for fremstilling derav, samt slike mikroemulsjoner for bruk som et medikament
MX21452A (es) Preparaciones farmaceuticas que se administran en forma topica.
NO317191B1 (no) S-omeprazol i noytral form, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende en slik form, og anvendelse derav
FR2720266B1 (fr) Tissu prothétique.
EE05075B1 (et) POL1212 aminohappej„rjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappej„rjestust omava valgu valmistamiseks
DK473888A (da) Peptid, fremgangsmaade til fremstilling deraf og laegemiddel indeholdende peptidet
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
ITRM930591A1 (it) Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
NO923756D0 (no) Osmotisk doseringssystem for avgivelse av vaeskeformig medikament
DE3585210D1 (de) Fuer kolonie stimulierenden faktor kodierende dns, dadurch kodiertes peptid, diese dns enthaltende vektoren und transformierte wirte und herstellung derselben.
NO309844B1 (no) Konserverte, humanproteinholdige legemidler for anvendelse som injeksjons- eller infusjonsoppløsning i form av flerdosepreparater
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
NZ520907A (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
KR970703768A (ko) 타크린 제약 조성물(Tacrine Pharmaceutical compositions)
BR9408377A (pt) Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
NO332750B1 (no) Anvendelse av nukleosider for fremstilling av et medikament for behandling av hepatitt C virus
DE69106549D1 (de) Thrombin-Zusammensetzung zur oralen Verabreichung.
EE9400455A (et) Peptiidi derivaadid, nende valmistamise protsess, neid sisaldavad ravimpreparaadid ja nende kasutamine
NO316865B1 (no) Ny oral farmasoytisk doseringsform, fremgangsmate for dens fremstilling, og anvendelse derav